UK-China AMR Collaboration Competition

Dear All: 

It is great to see that the UK Department of Health (DH) and the Chinese Ministry of Science and Technology (MoST) have today announced the size, scope and eligibility for the UK-China AMR Collaboration that was initially announced in 2016. DH will to invest up to £10 million in UK businesses and MoSt will provide to 60 million RMB to fund the Chinese partners. The competition will open at the start of 2018 — more precise dates will be announced in due course.

The aim is to support novel products or services against antimicrobial resistance (AMR) that neither country would be able to conduct within the same timeframe without the other’s expertise. Where appropriate, clinical evaluation can be supported. Specifically, the call will seek projects that:

  • explore opportunities from traditional Chinese medicine for the treatment or prevention of infectious diseases in humans or animals
  • advance the discovery of new agents to prevent or treat drug-resistant bacterial infection in humans or livestock. New agents could include small molecule drugs, vaccines, antibodies or other biological products
  • identify new agents that will increase the feed energy conversion in livestock. This should be done without use of antibiotics or hormones
  • maximise the clinical utility of current antibiotics. The aim is to improve the prognosis of patients with extensively drug-resistant infections
  • improve capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance

The Knowledge Transfer Network (KTN) and Innovate UK will be hosting a number of roadshows across the UK to publicise the competition as well as activity to support partnership building with Chinese researchers.  Gabriela Juarez Martinez from the KTN (gabriela.juarezmartinez@ktn-uk.org) can provide more information to interested researchers. Projects will need to comply with Official Development Assistance (ODA) criteria.

Well done to all for working to make this happen!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

The road to UNGA 2024 is paved with … reports!

Dear All, We’re now well into the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details). In preparation, reports providing data to support policy and decision-making are continuing to appear. Today, for example, GCOA and IDSA released their report entitled “2024

Leaving the lab: The decline in AMR R&D professionals

Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals” (press release, report itself), its key message of “Researchers Are Leaving the AMR Field – Even as the Threat Rapidly Grows” is illustrated vividly by the report’s graphics. I’m going

ADVANCE-ID seeks antibiotic for P2/3 development Asia!

Dear All, Yow! Led by David Paterson,  ADVANCE-ID (ADVANcing Clinical Evidence in Infectious Diseases) is a research group launched March 2023 as a network of more than 30 hospitals across Asia. The exciting news is that ADVANCE-ID have just announced that they are seeking a novel antimicrobial agent vs. MDR Gram-negatives that could be advanced in the clinic

Which came first: The drug or resistance to the drug?

Dear All, Although it seems entirely reasonable that the “Which came first?” chicken vs. egg riddle can be resolved in favor of the egg, a pair of papers in CID suggest that the answer to the parallel question of “drug vs. resistance to the drug” is changing in a way that is NOT in our favor!

Scroll to Top